Abiopharma

🔍 Dugel Pravin (Director)

Company: OCULAR THERAPEUTIX, INC (OCUL)

Report Date: 2026-08-24

Detailed Transactions and Holdings:

• Sold 21,649 shares of Common Stock at $10.77 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,525,429.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2
• Sold 50,092 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: G | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3
• Acquired 50,092 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: G | equity_swap_involved: 0 | shares_owned_after: 744,903.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6400 to $10.9000, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
• F3: On August 25, 2026, the reporting person's spouse transferred 50,092 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust.
• REMARKS: Executive Chairman, President and CEO